<DOC>
	<DOCNO>NCT01144468</DOCNO>
	<brief_summary>The NCIC CTG conduct international breast cancer prevention trial ( MAP.3 ) examine effect new therapy ( exemestane ) breast cancer prevention postmenopausal woman increase risk develop disease . Results show median follow 35 month , exemestane superior placebo breast cancer prevention . Exemestane block estrogen production , may beneficial prevent breast cancer , may negative effect bone . As postmenopausal woman risk develop osteoporosis , determine whether exemestane cause bone weaken crucial woman consider long-term use . Dr. Cheung 's team follow bone health 354 woman MAP.3 detail 2 year find volumetric bone mineral density ( high resolution peripheral quantitative computer tomography ( HR-pQCT ) radius tibia well areal bone mineral density dual energy x-ray absorptiometry ( DXA ) hip spine decrease significantly use exemestane . The long term effect exemestane bone examine 5 year therapy 2 year post therapy delineate effect exemestane bone strength . This research inform u safety exemestane breast cancer prevention .</brief_summary>
	<brief_title>Effects Exemestane Bone Strength</brief_title>
	<detailed_description>Aromatase inhibitor ( AIs ) substantially decrease estrogen level postmenopausal woman ; thus , potential prevent breast cancer , also potential adversely affect bone . Previous animal data group suggest exemestane , steroid AI , may favourable effect bone metabolism non-steroidal AIs . Over past year , conduct 2-year companion study subset woman participate 5-year MAP.3 trial -- primary breast cancer prevention trial conduct NCIC Clinical Trials Group ( NCIC CTG ) examine effect exemestane prevention breast cancer . This companion study conduct 3 geographic location ( Toronto , Canada ; Mayo Clinic Rochester ( US ) University California Davis California ( US ) ) postmenopausal woman osteoporosis baseline , investigate effect exemestane bone structure density first 2 year take exemestane . On November 5 2010 , MAP.3 study reach early primary breast cancer event-driven endpoint . Data analysis conduct March 2011 show median follow 35 month , exemestane superior placebo breast cancer prevention . Based upon positive result MAP.3 trial , relatively low incidence adverse event see woman receive exemestane compare receive placebo , trial committee NCIC CTG agree close study . Instead , modify observational study continue . We also extend 2-year study another 3 year . Recent data suggest difference change BMD ( perhaps fracture ) woman breast cancer , early effect ( &lt; 2 year ) bad late effect . As exemestane find effective prevention breast cancer , likely go use 5 year . By extend companion study another 3 year , able determine long term ( 5 year ) effect exemestane bone structure density , compare effect observe 2 5 year follow-up observe baseline 2 year . The primary objective original 2-year study extension study determine whether exemestane cause clinically statistically significant difference percent change total volumetric bone mineral density ( BMD ) distal radius measure high-resolution peripheral quantitative compute tomography ( HRpQCT ) baseline 2 year 2 5 year , 2 year post therapy , compare placebo . Our secondary objective : 1 ) determine effect exemestane cortical trabecular volumetric BMD measure pQCT scan 1 , 2 , 3 5 year ; 2 ) examine effect exemestane bone geometric parameter cortical thickness , trabecular thickness , trabecular separation trabecular number 1 , 2 , 3 5 year ; 3 ) investigate effect exemestane percent change BMD lumbar spine ( L1-L4 ) total hip measure dual energy X-ray absorptiometry ( DXA ) baseline 1 , 2 , 3 5 year compare placebo ; 4 ) determine effect 2 year exemestane bone strength index compare placebo . We also compare early ( baseline 2 year ) late ( 2 5 year ) effect exemestane bone . All participant companion study provide calcium vitamin D supplementation . Measurements volumetric BMDs bone geometric parameter obtain HRpQCT use Xtreme CT , measurement areal BMDs obtain DXA use Hologic Lunar densitometer baseline , 1 , 2 , 3 5 year , accord standard protocol . The result propose extension companion study help u understand long term effect long term safety exemestane bone health postmenopausal woman risk develop breast cancer . Data healthy postmenopausal woman take long term ( 2-5 year ) exemestane exist time . Information study help clinician woman weigh risk benefit use exemestane make informed decision regard breast cancer prevention .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Women participate MAP.3 clinical trial centre access HRpQCT 1 . Women osteoporosis ; 2 . Women Tscore 2.0 lumbar spine ( L1L4 ) , total hip femoral neck ; 3 . Women fragility fracture age 40 ; 4 . Women bone drug , hormone replacement therapy , selective estrogen receptor modulators , bisphosphonates , teriparatide , parathyroid hormone , sodium fluoride , strontium , calcitonin high dose vitamin D ( 2000iu vitamin D3 daily ) , past 3 month ; 5 . Women ever bisphosphonate 6 month ; 6 . Women ever strontium 1 month ; 7 . Women chronic oral steroid ( equivalent 5mg prednisone day high 2 week within past 6 month likely require ongoing therapy ) ; 8 . Women Paget 's disease , Cushing 's disease , hyperparathyroidism , uncontrolled hyperthyroidism metabolic bone disease ; 9 . Women decompensated disease liver , bowel , kidney , pancreas , lung , heart .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast cancer prevention</keyword>
	<keyword>osteoporosis</keyword>
</DOC>